Home

  • ACR Convergence 2026: Do Not Miss – Rare & Autoinflammatory Diseases

    Dr Magda Osipyan

    Magda is a clinician at Vardanants Medical Centre and an Associate Professor at Yerevan State Medical University.

    Her research interests are connected mainly with systemic lupus erythematosus, Behçet’s disease and familial Mediterranean fever. She is fond of organising conferences and training sessions and is currently working on establishing a patient educational school for rheumatology patients in Armenia.

    Magda is the secretary of Armenian rheumatological association and a member of the EMEUNET Visibility & Global Affairs Sub-Committee.

    Poster 0679| Sunday, 8.11.26, 10:30
    Poster Session A; Abstract 0679
    Presenting author: L. Muñoz (Spain)
    Title: Epidemiology of adult-onset Still’s disease in northern Spain: a 24-year population-based study

    This population-based study identified 26 cases of adult-onset Still’s disease (AOSD) in Cantabria, Spain, from 2000–2023. Estimated prevalence was 4.98 per 100,000 inhabitants and incidence 0.20 per 100,000 person-years. Fever and arthralgia/arthritis were present in 96%, rash in 77%, and inflammatory markers were markedly elevated. The increasing prevalence over time may reflect improved recognition and case capture through a centralized referral system.   
    Poster 1081| Monday, 9.11.26, 10:30
    Poster Session B; Abstract 1081
    Presenting author: E. Deniz Batu Akal (USA)
    Title: Loss-of-function in NLRC3 causes a human autoinflammatory disease

    Investigators describe a 24-year-old man with recurrent fever and multisystem symptoms from infancy, carrying a homozygous NLRC3 p.Leu90Pro variant. Functional experiments showed increased IL-1β, IL-6 and TNF-α after stimulation, heightened NF-κB activity and enhanced STING-associated interferon signaling. Wild-type, but not mutant, NLRC3 reduced inflammatory responses. The findings identify biallelic NLRC3 loss of function as a potential cause of human autoinflammatory disease and highlight a new innate-immune regulatory checkpoint.
    Poster 1625| Monday, 9.11.26, 10:30
    Miscellaneous Rheumatic & Inflammatory Diseases Poster B (1606–1643)
    Presenting author: N. Hershkowitz (USA)
    Title: Mixed NOD-like Receptor-Associated Autoinflammatory Disease

    This case series describes 11 adults with mixed NOD-like receptor-associated autoinflammatory disease, with variants in two or more genes including MEFV, TNFRSF1A, NLRP3, NLRP12 and NOD2. Common features included rash (100%), arthralgia (81.8%) and abdominal pain and diarrhea (72.7% each); two-thirds had raised acute-phase reactants. Many patients did not respond adequately to colchicine or hydroxychloroquine alone, while most required IL-1 inhibition and had significant clinical responses. The report emphasizes the diagnostic complexity of overlapping, oligogenic autoinflammatory phenotypes.
    Oral 1880| Monday, 9.11.26, 13:00
    Abstract Session: Miscellaneous Rheumatic & Inflammatory Diseases: Focus on Inflammatory and Fibro-Inflammatory Disease (1880–1885)
    Presenting author: H. Asad (USA)
    Title: Cardiac Manifestations in VEXAS Syndrome

    In a retrospective Mayo Clinic cohort of 130 patients with VEXAS syndrome (median age 70.5 years; 99.2% male), cardiac complications were frequent. During a median two-year follow-up, 23.1% developed conduction abnormalities and 32 patients experienced arrhythmias, most commonly atrial fibrillation or nonsustained ventricular tachycardia. New heart failure occurred in 14.6%, and overall mortality was 34.6%. The findings support careful cardiovascular assessment in VEXAS, while the observational design cannot establish causality.
    Oral 1881 | Monday, 9.11.26, 13:15
    Miscellaneous Rheumatic & Inflammatory Diseases: Focus on Inflammatory and Fibro-Inflammatory Disease (1880–1885)
    Presenting author: S Ugurlu (Türkiye)
    Title: Efficacy and safety of goflikicept, an IL-1β and IL-1α inhibitor, in familial Mediterranean fever: an international randomized clinical trial

    In this phase 2 randomized, double-blind trial, 33 adults with colchicine-resistant or colchicine-intolerant familial Mediterranean fever and active attacks received goflikicept or placebo. Complete treatment response occurred in 68.8% (11/16) of goflikicept-treated participants versus 11.8% (2/17) receiving placebo (p=0.001). Most adverse events were mild to moderate, and the safety profile was consistent with other IL-1 inhibitors. These results suggest IL-1α/IL-1β blockade may be a promising option for patients whose FMF is inadequately controlled by colchicine; larger studies are needed.
  • ACR Convergence 2026: Do Not Miss – Other connective tissue diseases and vasculitis

    Guillermo CARVAJAL ALEGRIA MD, PhD

    Guillermo is professor of rheumatology at the University of Tours and in the rheumatology department of the Tours University Hospital, France. His research interests are polymyalgia rheumatica and giant cell arteritis, ultrasonography and procedures for clinical research and administration of biopharmaceuticals for scientific research. He is part of the board of directors of the French Rheumatology Society and of steering committee of the French College of Teaching Rheumatologists.

    He is the chair of the EMEUNET Education sub-committee.

    Oral 0929| Sunday, 08.11.26 15:45
    Abstracts: Vasculitis – ANCA-Associated – Clinical (0926-0931)
    Presenting author: YK. Kim (Korea)
    Title: Efficacy and safety of add-on glucocorticoid pulse therapy during remission induction in patients with ANCA-associated vasculitis: a target trial emulation study

    This target trial emulation used a cohort of 247 patients with granulomatosis with polyangiitis or microscopic polyangiitis enrolled between 2004 and 2024. Remission (BVAS=0) at 12 months was similar with or without add-on glucocorticoid pulses during induction with rituximab or cyclophosphamide. Infections were more frequent in the pulse-treatment group..   
    Oral 1858| Monday, 09.11.26 08:00
    Abstracts: Sjögren’s Disease – Basic & Clinical Science (1856-1861)
    Presenting author: T. Grader-Beck (USA)
    Title: Salivary Gland Ultrasonography Severity Reflects Progressive Exocrine Dysfunction in Sjögren’s Disease

    This retrospective cohort study included 1,123 patients with Sjögren’s disease and OMERACT ultrasonography scoring of the major salivary glands. A grade of 3 in the most severely affected gland was associated with worse salivary flow, Schirmer test results and ocular staining scores than a grade of 0. The findings link greater ultrasonographic severity to more pronounced exocrine dysfunction.
    Oral 1822| Monday, 09.11.26 10:30
    Plenary II
    Presenting author: N. Yatim (France)
    Title: Clonal hematopoiesis orchestrates Giant Cell Arteritis Disease trajectory and immune landscape: a multicentric and multiomics approach

    This multicentre study found clonal haematopoiesis (CH) in approximately 50% of 260 patients with giant cell arteritis (GCA). CH was associated with relapse risk and a trend towards ischaemic manifestations. Transcriptomic and spatial transcriptomic analyses suggest links between CH and the vascular immune mechanisms of GCA.
    Oral 1985| Monday, 09.11.26 13:45
    Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders – Clinical (1892-1897)
    Presenting author: A. Dua (USA)
    Title: Effectiveness of Sarilumab versus Methotrexate as Glucocorticoid-sparing Therapy in Polymyalgia Rheumatica

    This retrospective database study compared 258 patients with polymyalgia rheumatica treated with sarilumab with matched methotrexate initiators. Median time to glucocorticoid discontinuation was shorter, and cumulative glucocorticoid exposure was lower, in the sarilumab group. These real-world findings support a glucocorticoid-sparing benefit of sarilumab, while recognising the observational design.
    Oral 2857 Tuesday, 10.11.26 13:00
    Abstracts: Epidemiology & Public Health II (2857-2862)
    Presenting author: J. Galloway (UK)
    Title: The impact of idiopathic inflammatory myopathies: A population-based cohort in England 2002 to 2021

    This UK population-based cohort identified 4,097 patients with idiopathic inflammatory myopathies. Mortality and cancer risks were higher than in controls during the first year after diagnosis. During subsequent follow-up of 2–19 years, the risks remained elevated without further increase. The study highlights sustained adverse outcomes, including excess cancer risk, in this population
  • ACR Convergence 2026: Do Not Miss – Metabolic & crystal arthropathies

    Dr. Mihai Turcu

    Mihai is a rheumatology resident at the Emergency Clinical County Hospital of Craiova, Romania, and a PhD candidate with a research focus on adipose tissue dysfunction and immunometabolic phenotypes in rheumatic diseases. His broader clinical and research interests span systemic autoimmune diseases, health economics, outcomes research, and the application of artificial intelligence in healthcare. He has co-authored several peer-reviewed publications investigating healthcare-related outcomes, quality of life, and disease burden in patients with rheumatic diseases.

    Poster 0124| Sunday, 08.11.26 10:30
    Poster Session A: Innate Immunity Poster
    Presenting author: J. Lee (South Korea)
    Title: Spatial and Transcriptomic Characterization of the Gouty Tophus as a Structured Inflammatory Microenvironment: Evidence for SPP1 ⁺ Macrophage-Fibroblast Crosstalk and Local Complement Activation

    This spatial transcriptomics study reveals that the gouty tophus is a highly organized inflammatory microenvironment driven by dynamic crosstalk between SPP1⁺ macrophages and tissue fibroblasts, offering novel cellular targets beyond traditional urate-lowering strategies.   
    Poster 0712| Sunday, 08.11.26 10:30
    Poster Session A: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster
    Presenting author: R. Kasiraj (USA)
    Title: Gout Flare Burden and Cardiorenal Outcomes With Glucagon-Like Peptide-1 Receptor Agonists Versus Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus and Gout: A Propensity-Matched Retrospective Study

    This propensity-matched cohort study found an association between GLP-1 receptor agonist use and lower gout flare rates and better cardiorenal outcomes compared to DPP-4 inhibitors in patients with co-existing diabetes and gout.
    Poster 0715| Sunday, 26.10.25 10:30
    Poster Session A: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster
    Presenting author: C. Diaz-Torne (Spain)
    Title: Isolated, Metabolic, and Hypertensive Gout: A Population-Based Cluster Analysis of 94,759 Patients

    By applying population-based cluster analysis to nearly 95,000 patients, this study categorizes gout into three distinct clinical phenotypes, paving the way for personalized therapeutic strategies based on metabolic and cardiovascular risk profiles
    Poster 1654| Monday, 09.11.26 10:30
    Poster Session B: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster
    Presenting author: L. Suarez-Zorrilla (Spain)
    Title: Prevalence and Factors Associated with Crowned Dens and Crowned Dens Syndrome in Patients with Calcium Pyrophosphate Arthritis

    This retrospective CPP crystal arthritis study reviewed CT scans in 173 of 328 patients. Crowned dens was detected in 102/173 (59.0%), and crowned dens syndrome in 27/173 (15.6%). Age and longer disease duration were independently associated with crowned dens. The syndrome was associated with a chronic inflammatory phenotype. These findings support reviewing available CT scans, while the hospital-based, CT-selected sample limits generalisability.
    Poster 2651| Tuesday, 10.11.26 10:30
    Poster Session C: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster
    Presenting author:P. Khanna (USA)
    Title: Pooled Results From the Phase 3 Trials of Nanoencapsulated Sirolimus Plus Pegadricase in Uncontrolled Gout: Characterization of Adverse Events of Special Interest

    This pooled analysis of the phase 3 DISSOLVE trials assessed adverse events with nanoencapsulated sirolimus plus pegadricase in uncontrolled gout. Gout flare rates were similar with high-dose treatment, low-dose treatment and placebo (42.5%, 44.3% and 43.3%). Stomatitis occurred in 9.2%, 3.4% and 0%, respectively. Sirolimus-associated events were generally mild to moderate and did not lead to treatment discontinuation. The analysis characterises tolerability rather than demonstrating reduced infusion reactions.
    Poster 2644 | Tuesday, 10.11.26 10:30
    Poster Session C: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster
    Presenting author:  P. Mandl (Austria)
    Title: Assessing the Reliability of the Ultrasound Semiquantitative Scoring System for Gout – a Patient-Based Reliability Study by the OMERACT Ultrasound Working Group

    This initial live-patient assessment by OMERACT showed overall moderate reliability for the proposed semiquantitative ultrasound scoring system in gout, highlighting the need for further studies to improve scoring accuracy and application.
  • ACR Convergence 2026: Do Not Miss – Artificial Intelligence

    Dr. Gagandeep Sukhija

    Gagan is a Consultant Rheumatologist in London, UK, with postgraduate qualifications in Internal Medicine and Rheumatology and an academic background spanning India and the UK. His interests include lupus, vasculitis, myositis, rheumatology-associated interstitial lung disease, mental health and equitable access to care.

    He is active in medical education, research and quality improvement, and is involved with the British Society for Rheumatology Mental Health Special Interest Group and the EMEUNET Social Media Sub-Committee.

    Poster 0515 Sunday, 08.11.26 10:30
    Research Methodology Poster A (0512-0530)
    Presenting author:  L. Bischof (Austria)
    Title: AI-assisted Screening: Evaluating ASReview for Systematic Literature Reviews for the Development of Rheumatology Recommendations

    This study evaluated AI-assisted screening across 45 systematic review datasets. Empirically derived stopping rules maintained approximately 95% recall while reducing screening to around 25–35% of records. Five independent validation datasets achieved 95.6% sensitivity. These findings suggest a practical way to reduce the workload of evidence synthesis for rheumatology recommendations..   
    Poster 0869| Sunday, 08.11.26 10:45
    Plenary 1 (0867-0871)
    Presenting author: : A. Pitliya (USA)
    Title: Artificial Intelligence in Rheumatology: A Comparative Evaluation of Guideline Concordance and Hallucination Risk Across Platforms

    This study compared five AI platforms across 60 rheumatology scenarios. OpenEvidence and ChatGPT achieved the highest guideline concordance, at 91.2% and 89.4%, respectively. Hallucination rates ranged from 3.8% to 18.1%. Clinically relevant errors occurred across all platforms, highlighting the continued need for clinician oversight when using AI for decision support.
    Poster 1878| Monday, 09.11.26 14:00
    Abstracts: Measures & Measurement of Healthcare Quality (1874–1879)
    Presenting author: I. Hernández Pérez (Spain)
    Title: Can a Guideline-Grounded Artificial Intelligence Scribe Support Rheumatology Consultation Prioritization from Patient Narratives? A Feasibility Study

    This feasibility study assessed an AI scribe in 21 simulated rheumatology consultations. The tool structured patient histories, flagged alarm features and generated justified priority scores. It exactly matched expert prioritisation in 62% of cases, with a mean absolute error of 0.62 on a 0–10 scale. These findings suggest potential to support referral workflows, pending evaluation in real-world practice.
    Oral 1897| Monday, 09.11.26 14:15
    Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders – Clinical (1892–1897)
    Presenting author: C.-J. Bauer (Germany)
    Title: Artificial Intelligence for Ultrasound-Based Detection of Giant Cell Arteritis

    This study developed a deep learning model using 3,800 vascular ultrasound images from 244 individuals. The best model achieved AUCs of 0.94 for axillary and 0.87 for temporal artery image classification. AI-assisted interpretation could improve access to GCA ultrasound assessment where expertise is limited. International validation across populations, examiners and ultrasound systems is underway.
    Poster 2243| Tuesday, 10.11.26 16:15
    Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster C (2228–2283)
    Presenting author: M. J. Sandino Bermudez (USA)
    Title: Deep Learning Prediction of Autoantibodies From ANA Immunofluorescence Images

    This study trained deep learning models to predict specific autoantibodies directly from ANA immunofluorescence images, with patient-level training, validation and test splits. Discrimination was strongest for antimitochondrial, anticentromere and anti-dsDNA antibodies, with AUCs of 0.993, 0.950 and 0.902, respectively. The findings suggest potential for image-based laboratory triage, pending further validation.
    Oral 2897| Tuesday, 10.11.26 16:15
    Professional Education (2893–2898)
    Presenting author: E. Balczewski (USA)
    Title: Artificial Intelligence (AI) Curriculum for Continuing and Graduate Medical Education: A Multi-Center Pilot

    This multicentre pilot delivered a four-hour AI curriculum across five healthcare systems and nine training programmes, including rheumatology fellows. Knowledge scores increased from 32.8% to 57.7%, alongside higher self-reported confidence. The study supports practical AI education for clinicians, although substantially lower post-survey participation limits interpretation: 183 participants completed some pre-survey items, compared with 51 post-survey participants.
    Oral 2965| Wednesday, 11.11.26 11:30
    Abstracts: Patient Education/Community Programs: Patient Knowledge and Awareness (2965–2970)
    Presenting author: M. Juárez-García (Spain)
    Title: Artificial Intelligence, Rheumatologist, or Both? A Blinded Comparative Evaluation of Responses to Patient Questions in Rheumatology

    This blinded study compared rheumatologist-written, AI-generated and clinician-reviewed AI answers to 20 patient questions. Twenty patients and 12 healthcare professionals evaluated the responses. Patient ratings were similar across approaches, while clinician review improved several professional-rated domains, including readability, utility and completeness. The findings support collaborative development of patient information with expert review before use.
     

  • ACR Convergence 2026: Do Not Miss – SLE & APS

    Prof. Marc Scherlinger

    Marc Scherlinger is a Professor of Rheumatology at Strasbourg University Hospitals, France. His main research interests include clinical and translational research in systemic autoimmune diseases, particularly systemic lupus erythematosus, with a focus on B-cell-targeted therapies, immune dysregulation, and thromboinflammation. He is actively involved in international research collaborations and initiatives aimed at advancing innovative therapies for severe autoimmune diseases.

    Oral 0877| Sunday, 08.11.26 09:45
    Abstracts: Systemic Lupus Erythematosus – Treatment: Clinical TrialsPresenting author: Q. Hu (China)
    Title: Subcutaneous RXIM002, a Targeted Lipid Nanoparticle Circular RNA Therapy, for In Vivo Anti-CD19 CAR T-Cell Generation in Refractory SLE

    This first-in-human study evaluated subcutaneous RXIM002, a targeted lipid nanoparticle delivering circular RNA to generate anti-CD19 CAR T cells in vivo, in six patients with refractory SLE. CAR T cells were detectable within 24 hours and persisted for up to 60 days, predominantly in effector memory T-cell subsets. All patients achieved substantial B-cell depletion and clinical improvement (mean SLEDAI-2K reduction of 8.3 points), with only grade 1 CRS and no ICANS or infections reported. These preliminary findings provide proof of concept for a non-viral, subcutaneous CAR T-cell approach, potentially simplifying access to cellular immunotherapies.
    Oral 0092| Sunday, 08.11.26 13:30
    Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations & Outcomes: SLE General Care
    Presenting author: J. Vasques-Landim (Brazil)
    Title: Coronary Artery Calcification is Common Among Systemic Lupus Erythematosus Patients Classified as Low Cardiovascular Risk by the ACC/AHA PREVENT™ Calculator

    This cross-sectional study investigated the performance of the ACC/AHA PREVENT™ cardiovascular risk calculator in 83 women with systemic lupus erythematosus (SLE) aged 40–60 years. Coronary artery calcification (CAC) was detected in 25.3% of patients. Notably, 57.1% of patients with detectable CAC were categorized as low risk by PREVENT™. The calculator showed limited discrimination for CAC (AUC 0.67), whereas a model incorporating age, serum albumin and the SLICC/ACR Damage Index achieved an AUC of 0.78. These findings highlight the limitations of conventional cardiovascular risk assessment in SLE and suggest that disease-specific factors may improve the identification of subclinical coronary atherosclerosis
    Oral 0932| Sunday, 08.11.26 15:00
    Abstracts: Antiphospholipid Syndrome
    Presenting author: A. Luta (USA)
    Title: Clinical and Laboratory Predictors of Recurrent Thrombosis in Patients with Thrombotic Antiphospholipid Syndrome (APS): A Prospective Analysis of the APS ACTION Registry

    This prospective international study investigated predictors of recurrent thrombosis in 732 patients with thrombotic APS from the APS ACTION Registry. Over a mean follow-up of 5.7 years, 82 patients (11%) experienced recurrent thrombosis. A history of microvascular disease was the only significant independent predictor of recurrence (HR 2.16, 95% CI 1.12–4.15), while elevated anti-β2GPI IgG levels showed a non-significant association. These findings identify microvascular involvement as an important factor for thrombotic risk stratification in APS, although the predictive model showed only modest discrimination.
    Oral 1848| Monday, 09.11.26 09:00
    Abstracts: Reproductive Issues in Rheumatic Disorders
    Presenting author: M. Hagen (Germany)
    Title: Pregnancies in Patients with Autoimmune Disease Receiving CAR T-Cell Therapy

    This international case series reported 14 pregnancies in 13 women previously treated with CD19 CAR T-cell therapy for autoimmune diseases, including eight with SLE. The report describes seven women who delivered, eight neonates assessed, six ongoing pregnancies and one elective termination. No disease flares occurred during pregnancy. Neonatal B-cell counts and immunoglobulin levels were normal, and no CAR T cells were detected. These preliminary findings are reassuring, but larger studies and longer follow-up are needed.
    Oral 1823| Monday, 09.11.26 10:45
    Plenary Session: Plenary II
    Presenting author: R. A. Furie (USA)
    Title: Obinutuzumab Induces Histologic Remission and Deep Kidney Parenchymal B-cell Depletion in Patients With Lupus Nephritis: Exploratory Analyses From a Phase III Trial

    This exploratory analysis of the phase III REGENCY trial evaluated 64 repeat kidney biopsies in patients with lupus nephritis treated with obinutuzumab or placebo. Obinutuzumab significantly increased histological remission and induced profound depletion of kidney-infiltrating B cells. Remarkably, among patients without complete clinical renal response, 52.6% achieved histological remission with obinutuzumab versus 8.3% with placebo. These findings provide evidence of deep tissue B-cell depletion with anti-CD20 therapy and highlight the discrepancy between clinical and histological responses in lupus nephritis.
    Oral 1862| Monday 09.11.26 13:00
    Abstract Session: Rheumatoid Arthritis – Treatment II: Phenotyping and Personalization
    Presenting author: I. Parodis (Sweden)
    Title: Post-Treatment Proteinuria Imperfectly Predicts Histological Remission in Lupus Nephritis: Repeat Biopsy Data from ReBioLup Support Reappraisal of Trial Endpoints

    This prospective multicentre ReBioLup analysis assessed 47 month-12 repeat kidney biopsies. Eight of 47 patients (17%) had proteinuria below 0.5 g/g despite significant renal inflammation (NIH activity index ≥4), while 5/47 (11%) had proteinuria above 1 g/g with minimal or no histological activity. The optimal proteinuria threshold for histological remission was 0.22 g/g (AUC 0.79). These findings demonstrate discordance between proteinuria and tissue activity and support reconsideration of proteinuria-based trial endpoints.
    Oral 2839| Tuesday, 10.11.26 08:00
    Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations & Outcomes III: SLE Future Directions
    Presenting author: E. Morand (Australia)
    Title: A New Endpoint for SLE Clinical Trials: The Treatment Response Measure for Systemic Lupus Erythematosus Clinical Trials (TRM-SLE)

    This international consensus initiative developed TRM-SLE, a novel, patient-centred treatment response measure for SLE clinical trials. Involving 125 clinicians, 27 patient representatives and 46 other experts, the framework defines clinically meaningful improvement across eight disease domains, including arthritis, skin manifestations, nephritis and serositis. Overall response is classified as TRM-100 (improvement in all active domains) or TRM-1 (improvement in at least one domain). This new endpoint aims to overcome limitations of existing composite measures, although validation in clinical trial datasets is ongoing.

  • ACR Convergence 2026: Do Not Miss – Basic and Translational Research II

    ACR Convergence 2026: Do Not Miss – Basic and Translational Research II

    Dr Nikolaos Vlachogiannis

    Country: Greece

    Nikos is a postdoctoral researcher in Rheumatology and a resident in Internal Medicine at the Medical School of the National and Kapodistrian University of Athens. His clinical and research interests focus mainly on systemic sclerosis.

    He serves as the EMEUNET Country Liaison for Greece and is a member of the EMEUNET Education Subcommittee. In addition, he is one of the Basic Science Group Coordinators for the EUSTAR Young Investigators.

    Oral 0888 | Sunday, 08.11.2026 09:30
    Session: Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease
    Presenting author: Carlo Tur (Germany)
    Title: Remodeling of the Cellular and Molecular Immune Landscape in Lymph Nodes Following CD19 CAR T-Cell Therapy

    This study shows that CD19 CAR T-cell therapy induces immune remodeling in lymph nodes of patients with autoimmune diseases. Long-term follow-up revealed repopulation predominantly by naïve B cells, near-absence of memory B cells, and progressive plasma cell loss. Early regulatory T-cell expansion and redistribution across lymph node compartments was associated with enhanced immunoregulatory signaling. These findings suggest that CAR T-cell therapy establishes a new immunological homeostasis, potentially explaining sustained drug-free remission and supporting its role as an immune-resetting treatment.   
    Oral (Plenary) 0870 | Sunday, 08.11.2026 11:00
    Session: Plenary I
    Presenting author: Aurélien Chepy (France)
    Title: Anti-Topoisomerase-1 Autoantibodies Exert Intranuclear Pathogenic Activity in Systemic Sclerosis Through FcRn-Dependent Trafficking

    This study shows that anti-topoisomerase-1 antibodies (ATA), detected in a subset of patients with systemic sclerosis (SSc), enter cell nuclei through neonatal Fc receptor (FcRn)-dependent trafficking, inhibit topoisomerase-1 activity, and induce DNA damage. This activates cGAS-STING signaling, promoting type I interferon responses and collagen production, thereby linking ATA directly to immune activation and fibrosis. FcRn blockade with efgartigimod prevented these effects in skin explants. These results demonstrate a direct pathogenic role for ATA in SSc.
    Oral 0915 | Sunday, 08.11.2026 13:15
    Session: Abstracts: Rheumatoid Arthritis – Translational Models and Mechanisms
    Presenting author: Jaeyeon Kim (USA)
    Title: Migration-dependent Synoviocyte-Endothelium Cross-talk in Rheumatoid Arthritis

    This study identifies a pathogenic interaction between fibroblast-like synoviocytes (FLS) and endothelial cells (ECs) in rheumatoid arthritis (RA). FLS actively migrate across synovial capillary walls, a process associated with disease activity. FLS migration was dependent on polycystin-1 (PKD1) and induced endothelial cathepsin K (CTSK) expression, promoting angiogenesis and vascular permeability. Experimental PKD1 inhibition reduced FLS migration and arthritis severity. These findings reveal a strong interplay between FLS and ECs promoting synovial inflammation in RA.
    Oral 1850| Monday, 09.11.2026 08:00
    Session: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Basic and Translational Science
    Presenting author: Isabel Risch (USA)
    Title: Defining A Signature of Autoreactive CD8+ T Cells in HLA-B27-Associated Autoimmune Disease

    This study identifies a conserved transcriptional and functional signature of autoreactive CD8+ T cells across HLA-B27-associated inflammatory diseases. These cells exhibit a distinct type 17-like phenotype, characterized by IL-17A and IL-22 production, and share transcriptional features across blood, intestine, inflamed joints, and eyes. Detection of autoreactive T-cell receptors in intestinal samples suggests that their pathogenic differentiation may originate in the gut. These findings support a common immunological mechanism underlying HLA-B27-associated diseases.
    Oral 1821| Monday, 09.11.2026 10:15
    Session: Plenary II
    Presenting author: Benjamin Jones (USA)
    Title: Molecular Heterogeneity in Preclinical Lupus: Distinct Longitudinal Proteomic Trajectories Preceding Disease Progression.

    This study identifies three distinct soluble proteomic trajectories among individuals with incomplete lupus: Group 1 showed increasing interferon-immune responses associated with systemic/hematologic progression. Group 2 showed downregulation of innate immune signaling associated mainly with articular/mucocutaneous progression. Group 3 displayed relatively stable immune profiles and predominantly cutaneous progression. These results suggest that baseline proteomic profiling could improve risk stratification and guide personalized SLE prevention strategies.
    Oral 1904| Monday, 09.11.2026 15:00
    Session: Abstracts: Systemic Lupus Erythematosus – Etiology & Pathogenesis
    Presenting author: Rayan Najjar (USA)
    Title: Neoantigens Recognized by B and T Cells are Generated by Aberrant mRNA Splicing in Lupus Neutrophils

    This study identifies aberrant mRNA splicing in neutrophils of lupus patients. Researchers detected 271 lupus-specific cryptic splicing events across 130 protein-coding genes, including many interferon-stimulated genes. Experimental validation confirmed their translation and binding to MHC-I, and demonstrated both IgG antibody responses and antigen-specific T-cell activation against these cryptic peptides. The abnormalities were enriched in neutrophils and were not reproduced by type I interferon stimulation. These findings reveal cryptic splicing-derived neoantigens as potential drivers of immune activation in lupus.
  • ACR Convergence 2026: Do Not Miss – Basic and Translational Research I

    ACR Convergence 2026: Do Not Miss – Basic and Translational Research I

    Dr Fatma Gül Demirkan
    Country: Türkiye

    Dr. Demirkan is an Associate Professor and pediatric rheumatologist at Kanuni Sultan Süleyman Training and Research Hospital in Istanbul, Türkiye. She is currently pursuing her MSc in Autoinflammatory Diseases in Children (thesis program) at İstanbul University, İstanbul Faculty of Medicine.

    Her clinical and research interests focus on autoinflammatory and autoimmune diseases in children, including familial Mediterranean fever, juvenile idiopathic arthritis, and systemic lupus erythematosus. She serves as the Clinical Lead of the PReS EMERGE Research Subcommittee and participates in several international multicenter collaborations. Dr. Demirkan is a member of the Pediatric Rheumatology European Society (PReS), EMEUNET (social media subcommittee) and PRINTO networks.

    Poster 0076| Sunday, 08.11.2026 10:30–12:30
    Session: Spondyloarthritis Including Psoriatic Arthritis – Basic and Translational Science Poster A (0069-0077)
    Presenting author: Semini Beragama Jathunga (Canada)
    Title: Sex-Specific Biomarkers in the Transition to PsA: Longitudinal Metabolomic Analyses

    This longitudinal study identified sex-specific metabolic changes accompanying the transition from psoriasis to psoriatic arthritis. Alterations involved inflammatory lipid signalling and mitochondrial function, with greater amino acid disturbances in males and lipid changes in females. These findings highlight potential biomarkers for earlier detection and sex-informed risk assessment, pending validation.   
    Poster 0026| Sunday, 08.11.2026 10:30–12:30
    Session: Systemic Sclerosis & Related Disorders – Basic and Translational Science Poster A (0022-0038)
    Presenting author: Neha Khanna (USA)
    Title: Defining the role of TEADs and VGLL3 in scleroderma endothelial cells

    This experimental study identified TEAD3 and VGLL3 as key regulators of endothelial-to-mesenchymal transition in systemic sclerosis. Silencing either factor reduced profibrotic markers and improved angiogenic capacity, highlighting potential therapeutic targets to preserve endothelial function and limit fibrosis-associated vascular injury.
    Poster 0008| Sunday, 08.11.2026 10:30–12:30
    Session: Vasculitis – Basic and Translational Science Poster A (0001-0008)
    Presenting author: Ingrid Lindquist (USA)
    Title: Transcriptome analysis of temporal artery and aortic lesions highlights vessel-specific chemotaxis and cell adhesion in GCA

    This transcriptomic study revealed vessel-specific chemotaxis and cell adhesion signatures in giant cell arteritis, highlighting CCL22 in temporal arteries and CXCL13 in aortic lesions. These findings may help explain distinct patterns of vascular involvement and guide the development of biomarkers and targeted therapies.
    Poster 0070| Sunday, 08.11.2026 10:30–12:30
    Session: Spondyloarthritis Including Psoriatic Arthritis – Basic and Translational Science Poster A (0069-0077)
    Presenting author: Thomas Macleod (United Kingdom)
    Title: Dual IL-17A/IL-17F Inhibition Modulates Entheseal Stromal Inflammatory Networks and Reveals a Role for IL-17F in Neutrophil Recruitment in Human Entheseal Inflammation.

    This experimental study showed that dual IL-17A/IL-17F blockade with sonelokimab more broadly suppressed entheseal stromal inflammatory pathways than IL-17A inhibition alone, reducing neutrophil recruitment and degranulation. These findings highlight IL-17F as a contributor to persistent entheseal inflammation and provide a mechanistic rationale for dual inhibition.
    Poster 0117| Sunday, 08.11.2026 10:30–12:30
    Session: Muscle Biology, Myositis, & Myopathies – Basic and Translational Science Poster A (0117-0120)
    Presenting author: Karen Gambina (USA)
    Title: A Population of CD57⁺ CD8⁺ T Cells With Cytotoxic Potential Are Expanded in Immune-Mediated Necrotizing Myopathy and Dermatomyositis

    This exploratory study identified expanded CD57⁺ CD8⁺ T-cell populations with cytotoxic potential in immune-mediated necrotizing myopathy and dermatomyositis, including during clinical remission. These findings suggest persistent immune abnormalities despite apparent disease inactivity and highlight the need to investigate their role in muscle injury and future flares.
  • ACR Convergence 2026: Do Not Miss – Rheumatoid arthritis (therapeutic)

    ACR Convergence 2026: Do Not Miss – Rheumatoid arthritis (therapeutic)

    Dr Joanna Kedra
    Country: France

    Joanna is a rheumatologist at Sorbonne University and the Department of Rheumatology at Pitié-Salpêtrière Hospital in Paris, France. Her research focuses on the benefit-risk balance of targeted therapies in rheumatoid arthritis using large real-world healthcare databases. She has contributed to the development and updating of recommendations for both the French Society of Rheumatology (SFR) and EULAR. Joanna is a member of the EMEUNET Newsletter Sub-Committee.

    Poster 0441| Sunday, 08.11.2026 10:30–12:30
    Session: Poster Session A: Rheumatoid Arthritis – Treatment
    Presenting author: R. Kasiraj (USA)
    Title: Cardiovascular Outcomes of Upadacitinib/Baricitinib Versus Tofacitinib in Rheumatoid Arthritis: A Propensity-Matched Retrospective Study

    In this propensity-matched real-world study of >27,000 rheumatoid arthritis patients, tofacitinib was associated with significantly higher all-cause mortality (RR 1.78, 95% CI 1.63-1.95) and composite MACE (RR 2.41, 95% CI 2.11-2.75) compared to upadacitinib/ baricitinib. Tofacitinib also showed consistently higher risks for myocardial infarction, stroke, heart failure, and thromboembolic events. These observational findings suggest lower cardiovascular risk with upadacitinib/baricitinib than with tofacitinib in this cohort; they do not establish causality.   
    Poster 0467| Sunday, 08.11.2026 10:30–12:30
    Session: Poster Session A: Rheumatoid Arthritis – Treatment
    Presenting author: L. Kawka (France)
    Title: Safety and effectiveness of 265 combinations of targeted therapies in immune mediated inflammatory diseases : data from the COMBATT registry

    This real-world study evaluated combination targeted therapies (cTT) in 204 patients with immune-mediated inflammatory diseases (IMIDs). cTT was mainly initiated for single refractory IMIDs (48.0%) or coexisting IMIDs (51.9%). Treatment was effective or partially effective in 62.3% of single refractory cases with an acceptable safety profile (severe infections incidence: 5.2/100 patient-years), though these results have to be confirmed by larger, longer studies.
    Oral 1898| Monday, 09.11.2026 15:00
    Session: Rheumatoid Arthritis – Treatment
    Presenting author: D. Yesho (USA)
    Title: GLP-1 receptor agonist for primary prevention of DMARD-associated malignancy in patients with Rheumatoid Arthritis taking DMARDs: A multi-center real-world analysis

    In this propensity-matched real-world study of 24,142 rheumatoid arthritis patients on DMARDs, GLP-1 receptor agonists (GLP-1 RAs) were associated with a significant reduction in malignancy risk. Over a 5-year follow-up, GLP-1 RA use was associated with a 38% risk reduction in incident lung cancer and a 52% risk reduction in non-Hodgkin lymphoma. These results suggest a potential protective role for GLP-1 RAs against DMARD-associated malignancies, possibly through anti-inflammatory, immunomodulatory, and direct anti-proliferative mechanisms.
    Oral 1899| Monday, 09.11.2026 15:15
    Session: Rheumatoid Arthritis – Treatment
    Presenting author: G. Valenzuela (USA)
    Title: AB-101, Outpatient-Administered, Non-Genetically Modified NK Cells, in Combination with Rituximab Generate Robust Efficacy Responses Comparable with Autologous CAR T in 34 Patients with Rheumatologic Diseases

    In a Phase 2a basket study of 34 patients with treatment-refractory autoimmune diseases (rheumatoid arthritis, Sjögren’s disease, systemic sclerosis), outpatient AB-101 (NK cells) plus rituximab achieved deep B-cell depletion and robust, sustained clinical improvements at 6 months. This combination delivered CAR-T-like efficacy without severe toxicities such as CRS, ICANS, or GvHD. These results highlight a promising, convenient outpatient therapy for refractory rheumatologic conditions.
    Oral 1903| Monday, 09.11.2026 16:15
    Session: Rheumatoid Arthritis – Treatment
    Presenting author: C. Immediato Daien (France)
    Title: Dietary Fibre Supplementation improves Rheumatoid Arthritis and Th17/Treg Balance: Results from the SUPERFIBRES Randomized Controlled Trial.

    In a randomized controlled trial of 48 rheumatoid arthritis patients on DMARDs, 30-day inulin fibre supplementation significantly increased EULAR response rates (OR 4.65, 95% CI 1.15-18.9) compared to placebo. Fibre intake also reduced circulating Th17 cells and improved the Th17/Treg immune balance, while inducing distinct gut microbiota shifts. These findings suggest dietary fibre is a safe, low-cost adjunct to enhance methotrexate efficacy in RA.
    Poste 2405| Tuesday, 10.11.2026 10:30–12:30
    Session: Poster Session C: Rheumatoid Arthritis – Treatment
    Presenting author: M. Movahedi (Canada)
    Title: Oral Glucocorticoid Use and Discontinuation Among JAK inhibitors and Biologic DMARDs in Rheumatoid Arthritis: A Canadian Retrospective Cohort Study

    In this real-world study of rheumatoid arthritis patients initiating targeted therapies, oral glucocorticoid (GC) use declined over 36 months across all drug classes (JAKi, TNFi, non-TNFi bDMARDs). JAKi demonstrated comparable GC-sparing effectiveness to bDMARDs, with no significant differences in GC discontinuation rates. However, JAKi users achieved numerically lower GC exposure and significantly lower daily doses at 36 months compared to TNFi users.
    Oral (Plenary) 2807| Tuesday, 10.11.2026 11:00
    Session: Plenary III
    Presenting author: E. Roberts (USA)
    Title: Equivalent effectiveness but decreased persistence in patients switched to biosimilar infliximab: evidence from real world data

    In this real-world study of rheumatoid arthritis patients from the RISE registry, switching from originator to biosimilar infliximab maintained equivalent disease control, with no increase in flares or uncontrolled disease. However, switchers demonstrated significantly lower treatment persistence over one year compared to non-switchers (274.6 vs 311 days, p < 0.01). These findings support comparable clinical effectiveness but lower persistence after switching; the reasons for this difference require further study.

  • ACR Convergence 2026: Do Not Miss – Rheumatoid arthritis (non-therapeutic)

    Dr Rosanna Campitiello
    Country: Italy

    Rosanna is a rheumatologist and PhD candidate in Clinical and Experimental Immunology at the University of Genova, Italy, where she works at the Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology. Her major research interests are systemic sclerosis, rheumatoid arthritis, innate immunology in connective tissue disease, and nailfold videocapillaroscopy

    Rosanna is a member of the EMEUNET Education Sub-Committee

    Poster 0503| Sunday, 08.11.2026 10:30–12:30
    Session: Poster Session A: Rheumatoid Arthritis – Diagnosis, Manifestations, & Outcomes
    Presenting author: A. Phothisane (USA)
    Title: Respiratory infections and ILD progression account for more than 60% of deaths in RA-ILD: results from a multicenter cause-specific mortality analysis

    In this retrospective multicenter study, deceased RA-ILD patients were identified through electronic records from three French tertiary referral centers (2009-2026). The leading primary causes of death were infections (34.8%, mostly respiratory, including 9 COVID-19 deaths) and ILD progression or acute exacerbation (31.5%). ILD was directly or indirectly involved in 60.9% of deaths. Patients with FVC <80% at diagnosis more often died of ILD-related causes (48.7% vs 18.2%; p=0.005), whereas cardiovascular deaths prevailed when lung function was preserved (18.2% vs 2.6%; p=0.032).   
    Oral 1834| Monday, 09.11.2026 08:30
    Session: Rheumatoid Arthritis – Diagnosis, Manifestations, & Outcomes: Preclinical RA
    Presenting author: A. Di Matteo (United Kingdom)
    Title: Ultrasound-detected bone erosions during the preclinical phase identify a severe disease trajectory in CCP+ individuals following inflammatory arthritis development.
    In the Leeds CCP cohort, 193 CCP+ at-risk individuals who progressed to inflammatory arthritis (IA) were analysed. Pre-IA ultrasound erosions were found in 37.3% (most often at the fifth MTP), whereas radiographic erosions were present in only 5/72 (6.9%) of the ultrasound-erosion-positive subgroup. These progressors had higher b/tsDMARD use (50.7% vs 31.9%; p=0.013) and more difficult-to-treat disease (15.5% vs 6.0%; p=0.042). The number of erosions predicted radiographic damage. Preclinical ultrasound erosions may identify a severe disease trajectory.
    Oral 1836| Monday, 09.11.2026 09:00
    Session: Rheumatoid Arthritis – Diagnosis, Manifestations, & Outcomes: Preclinical RA
    Presenting author: L. Duquenne (United Kingdom)
    Title: Catching the window for interception in individuals at risk of developing inflammatory arthritis: design of a dynamic “Imminent Risk Score”

    In 543 anti-CCP+ individuals with musculoskeletal symptoms, of whom 176 (32.4%) progressed to inflammatory arthritis, a dynamic “Imminent Risk Score” applicable at any visit was developed. Four features predicted progression within 6 months: anti-CCP ≥3x ULN, elevated RF, morning stiffness ≥30 minutes and ≥1 small tender joint. Discrimination was comparable to the previously published Baseline Risk Score (C-index 0.864 vs 0.856). When all four features were present, specificity reached 86.3% (positive predictive value 46.2%): nearly 1 in 2 individuals progressed within 6 months. The score may help select candidates for interception trials.
    Poster 1444| Monday, 09.11.2026 10:30–12:30
    Session: Poster Session B: Rheumatoid Arthritis – Diagnosis, Manifestations, & Outcomes
    Presenting author: G. McDermott (USA)
    Title: Genes and genetic variants associated with non-response to multiple targeted therapies in rheumatoid arthritis: an analysis using whole genome sequencing data.

    Whole genome sequencing was performed in 243 RA patients: 157 non-responders to multiple b/tsDMARDs from the RANT study, 105 of them treatment-refractory, and 86 TNFi responders as controls. Three variants reached genome-wide significance for association with the number of b/tsDMARDs used, and one gene (RBM38-AS1) was associated at gene level (FDR <0.10). No variant or gene distinguished treatment-refractory patients from TNFi responders. External validation is needed.
    Poster 1436| Monday, 09.11.2026 10:30–12:30
    Session: Rheumatoid Arthritis – Diagnosis, Manifestations, & Outcomes Poster B
    Presenting author: T. O’Malley (USA)
    Title: Convergent Temporal, Clinical, and Geographic Evidence for Association Between Borrelia and Anti-RA33 Immune Response Identified by Analysis of 148,839 Patients

    In 148,839 multi-analyte autoimmune panel orders, anti-RA33 IgG positivity (emerging biomarker for RA) showed a seasonal pattern, peaking in May (12.4%) and falling in December (6.9%) (warm vs cold months OR 1.40, 95% CI 1.35-1.45). Anti-CCP and SLE markers did not vary by season. The seasonal effect was stronger in states with high Lyme incidence (median OR 1.50 vs 1.35; p=0.016), and anti-RA33 IgM tended to be higher in Lyme-coded patients (OR 2.03; p=0.052). Anti-RA33 IgG should be interpreted taking Lyme exposure into account.
    Poster 1430| Monday, 09.11.2026 10:30–12:30
    Session: Poster Session B: Rheumatoid Arthritis – Diagnosis, Manifestations, & Outcomes
    Presenting author: I. Usiskin (USA)
    Title: Association Between GlycA and Vascular Inflammation in Rheumatoid Arthritis: Secondary Analysis of the TARGET Randomized Trial Comparing TNF Inhibition With Triple Therapy

    In a secondary analysis of the TARGET trial, 111 RA patients with inadequate response to methotrexate were treated with triple therapy or a TNF inhibitor for 24 weeks. Arterial inflammation was measured by FDG-PET/CT at baseline and at 24 weeks. Reduction in GlycA, a composite inflammatory biomarker, correlated with reduction in arterial inflammation, independently of hsCRP (β=0.14; p=0.047). In conclusion, GlycA may reflect changes in vascular inflammation in RA.
  • Wish I Knew This Earlier

    Wish I Knew This Earlier

    Composite Scores: What’s Behind the Number?

    From Dafne Capelusnik

    As rheumatology fellows, we quickly become familiar with an alphabet soup of composite scores: DAS28, SDAI, DAPSA, PASDAS, SLEDAI… We learn their cut-offs, what constitutes response or remission, and when they should guide treatment decisions. But we may spend much less time asking a simple question: what does that final number actually represent?

    In “Use of multidimensional composite scores in rheumatology: parsimony versus subtlety”, Robert Landewé and Désirée van der Heijde challenge the intuitive idea that combining more information into a single score necessarily provides a better picture of our patient.

    Composite scores have undeniable advantages. By combining several measures, they can reduce variability, improve the signal-to-noise ratio, and increase statistical power (exactly what we want in a clinical trial). But this parsimony comes at a price, especially in clinical practice: subtlety. By reducing complexity to a single number, we may lose information about what is actually happening in an individual patient.

    Rheumatic diseases are inherently multidimensional, although to very different degrees. SLE is perhaps the clearest example: myositis, nephritis, arthritis, skin or haematological involvement may appear independently and do not necessarily change together. PsA provides another intuitive example: arthritis, enthesitis, dactylitis, skin and nail disease may coexist, but improvement in one domain does not guarantee improvement in another. A multidimensional composite nevertheless attempts to summarise these potentially independent dimensions into a single number.

    But multidimensional composites are only part of the story. Even a composite designed to measure a single dimension can become more difficult to interpret when the context in which it is used changes. And the challenge becomes particularly relevant when that number is not only used to describe disease, but also to guide treatment decisions, as happens in treat-to-target strategies.

    Consider the DAS. Originally developed to assess disease activity in patients with active Rheumatoid Arthritis, its components reflected different perspectives of predominantly the same dimension (arthritis). But the context in which we use these scores has changed. In a patient with little objective inflammation, persistent pain or tender joints may reflect other mechanisms, such as central sensitisation, rather than ongoing inflammation. A high score may therefore persist despite little residual inflammation. Landewé and van der Heijde describe this as “dimension creep”: a measure that was originally largely unidimensional may acquire additional dimensions when used in a different clinical context.

    Another important lesson is to distinguish the disease process from its consequences. Inflammation happens now, whereas damage and functional impairment may partly reflect what happened in the past. Yet some composites mix them together. The authors use the HAQ (Health Assessment Questionnaire) within the ACR20 response criteria and MDA (Minimal Disease Activity) as an example. Functional impairment may closely reflect inflammation in early active disease, but the same HAQ score can have a very different meaning in a patient with longstanding, currently quiescent disease, in whom part of that impairment may be irreversible.

    This leads to perhaps the most clinically relevant lesson of the paper: a useful clinical trial endpoint is not necessarily a good treatment target. Two patients may have the same “high” composite score (or fail to reach the same target) for entirely different reasons. If residual pain, irreversible functional impairment, or another non-inflammatory component is driving the score, simply escalating anti-inflammatory treatment may not help and could even lead to overtreatment.

    The score tells us how high. Its components may tell us why.

    Perhaps the most useful habit this paper taught me is therefore not to stop at the final number. When interpreting a composite score, ask: What are its components? Are they measuring the same construct? Are we mixing the disease process with its consequences? Was this score developed for the context in which I am using it? And, most importantly, what is actually driving the score in this patient?

    Composite scores help us simplify complex diseases. They are invaluable tools, particularly in clinical research, but simplification should not replace clinical interpretation. As Landewé and van der Heijde remind us, parsimony in outcome assessment can come at the cost of clinical subtlety.

    References

    Landewé RBM, van der Heijde D. Use of multidimensional composite scores in rheumatology: parsimony versus subtlety. Ann Rheum Dis. 2021 Mar;80(3):280-285. doi: 10.1136/annrheumdis-2020-216999. Epub 2020 Nov 3. PMID: 33144304.